VANCOUVER, British Columbia, March 01, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, reports unaudited Q3 revenues for the period ended December 31, 2017 of $5.89 million CDN a for net operational profit of $202,254 CDN.

In comparison to the fiscal Q2 revenues, Q3 represents a 16% increase. The company is very pleased to report these revenues and attributes the growth and profit increase to increased distribution, reduced manufacturing costs, portfolio diversification, and the continued integration of wholly owned subsidiaries. 

Since the beginning of fiscal Q4, which commenced January 1, the Company has continued to gain traction in international markets such as Latin America and Europe and will continue to pursue additional global expansion. The Company has also made significant traction in operations with wholly owned subsidiaries such as ISO-Sport, Be Tru Wellness, and Bradley’s Bioscience.

Marcos Agramont, CEO of Isodiol International Inc. stated, “Over the last quarter, we continued to expand our footprint in the Latin American and European markets, while also gaining access to mainstream distribution channels in North America. Q3 produced strong results for the Company and as we continue to integrate our recent acquisitions and establish global operations, we anticipate further growth for the Company.”

For more information on Isodiol, please visit 

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook:
Twitter: @isodiol 

Marcos Agramont, CEO & Director


Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Primary Logo